.png)
AstraZeneca Pharma India has received CDSCO approval for Durvalumab with FLOT chemotherapy, making it the first perioperative immunotherapy option for adults with resectable gastric and gastroesophageal junction cancer.
Alembic Pharmaceuticals has received final USFDA approval for Difluprednate Ophthalmic Emulsion, 0.05%, used to treat post-surgery eye inflammation and anterior uveitis, further strengthening its US generics portfolio.
In a first-of-its-kind initiative, Gleneagles Hospital has introduced an AI-enabled Hub-and-Spoke stroke model that connects diagnostic centers across Mumbai and Navi Mumbai to its stroke team in real time, helping detect strokes early, reduce...
Natural Remedies shines at IPPE 2026, showcasing its science-backed phytogenics like NR-SBP. Their focus on sustainability, animal care, and productivity sets a new industry standard.
Roche has reported striking Phase II data for its CT-388 obesity drug, with patients achieving up to 22.5% weight loss over 48 weeks and strong metabolic improvements, supporting rapid advancement into Phase III trials.
Lubrizol will participate in WHX Dubai 2026, spotlighting its expanding medical device manufacturing capabilities and new investments in India, including a high-precision medical tubing facility in Chennai set to open mid-2026.
.jpeg)
Union Health Ministry drafts rules mandating blue strip on antimicrobial drugs to curb AMR. Public comments invited; aligns with PM Modi’s antibiotic safety emphasis.
Sanofi’s amlitelimab, a promising treatment for moderate-to-severe atopic dermatitis (AD), has shown robust results in two global Phase 3 studies. The findings, along with a favorable safety profile, highlight its potential to improve patients’ quali
Sun Pharmaceutical Industries has received DCGI approval for Noveltreat, a generic semaglutide injection designed to help with weight management. The treatment offers a cost-effective solution to combat obesity and related conditions.
Moderna and Merck’s personalized skin cancer vaccine shows a 49% reduction in recurrence risk after five years, offering new hope for high-risk melanoma patients.
.jpg)
, CDSCO.jpg)